undamentalytics Newsletter
Sign in

Calidi Biotherapeutics, Inc. (CLDI) stock

Add to watchlist

Add holding +

NYSE: CLDI NYSE Biotechnology

Calidi Biotherapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades

The Fundamentalytics view

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 32% in the quarter to 2025-09-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Calidi Biotherapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 94% and a beta of 2.3 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2022 Q4

Filed March 15, 2024
Earnings per share
-$35.36 against an average estimate of -$26.88: missed by 31.5%
Share reaction
-2.5% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500

Calidi Biotherapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.4%
  • 1 week+2.8%
  • 1 month-39.1%
  • This year-96.5%
  • 1 year-97.3%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Results
  4. Governance
  5. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Calidi Biotherapeutics, Inc. valuation models and calculator

No model value for Calidi Biotherapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Calidi Biotherapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.9 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Calidi Biotherapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Calidi Biotherapeutics, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2025 −$26.88 −$35.36 −31.5%
Jun 2025 −$21.12 −$31.89 −51.0%
Mar 2025 −$28.80 −$35.94 −24.8%
Dec 2024 −$71.04 −$51.84 +27.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
4.5%
of tradable shares
Days to cover
0.81
at average volume
Short interest, 1 month
−28%
to October 15, 2026
Held by institutions
1%
of shares
Held by insiders
0.6%
of shares
Employees
29
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
CLDI+4%−85%−92%−92%−97%
Industry peers (median)−57%−17%−28%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
CLDI83%50%25%25%0%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
CLDI−7%−87%−95%−94%−97%
S&P 500−25%−10%−8%−19%−9%

Worst fall since November 1, 2021: 100% from August 16, 2023 to October 26, 2026. Getting back needed a 3206900% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.64 – $26.56
From 52-week high
−97.5%
vs 50-day average
−37.7%
vs 200-day average
−84.9%
Volatility (1 year)
94%
Beta vs S&P 500
2.27

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 11 down
typical move ±6.4%
After a week
3 up, 9 down
typical move ±18.1%
After a month
1 up, 11 down
typical move ±24.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −2.5% +0.5% −17.8% −25.2%
May 14, 2026 −7.0% −0.4% −4.0% −19.0%
March 27, 2026 −14.9% −2.0% −12.8% −20.3%
January 29, 2026 −1.0% −0.5% −18.3% −24.1%
November 13, 2025 −0.7% −1.7% −8.6% −11.9%
August 8, 2025 −12.5% +0.6% −8.0% −71.4%
May 14, 2025 −5.0% +0.6% −7.3% −21.1%
March 31, 2025 −14.3% +1.0% −23.7% −25.7%
January 28, 2025 −2.4% +0.4% +100.0% +26.2%
November 13, 2024 −4.7% −0.6% +8.5% −12.3%
August 14, 2024 −4.8% +2.0% −8.2% −29.7%
May 15, 2024 +7.1% +1.0% +0.4% −9.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022
Income
Revenue 0
EBITDA −23
Operating income −23
Net income −25
Diluted EPS $29.90
Margins
EBITDA margin <−999%
Operating margin <−999%
Net margin <−999%
Cash flow
Cash from operations −13
Stock-based pay 5
Balance sheet
Cash 1
Total debt 7
Net debt (negative = net cash) 6
Diluted shares —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1,241 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $1,241 net selling
Insider Date Trade Shares Price Value
Camaisa Allan Director December 12, 2025 Sell 850 $1.46 $1,241

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 13, 2026
  • May 14, 2026
  • March 27, 2026
  • January 29, 2026
  • November 13, 2025
  • August 8, 2025

Recent SEC filings

Data status

When each part of this page on Calidi Biotherapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Calidi Biotherapeutics, Inc. in brief

What does Calidi Biotherapeutics, Inc. do?
Calidi Biotherapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Calidi Biotherapeutics, Inc.'s stock ticker?
Calidi Biotherapeutics, Inc. trades under the ticker CLDI on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Calidi Biotherapeutics, Inc.'s market cap?
On December 30, 2022, Calidi Biotherapeutics, Inc.'s market capitalisation was about $16.6B and net debt of $6.1M. Market figures come from third-party market data and may be delayed.
Are insiders buying or selling Calidi Biotherapeutics, Inc. stock?
Over the last 12 months, Calidi Biotherapeutics, Inc.'s directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.